Skip to main content Skip to navigation

 

 

In combination with the BD OneFlow™ LST, it is intended as an aid in the diagnosis of chronic lymphocytic leukemia (CLL) and other B cell chronic lymphoproliferative diseases.

 

 

Overview

The BD OneFlow™ B-CLPD T1 is part of the innovative BD OneFlow™ Solution, a comprehensive set of reagents, setup beads, protocols and assay templates to reproducibly set up the flow cytometer and stain, acquire and analyze patient specimens for immunophenotyping of normal and aberrant cell populations. It is built on the research and validation work of the EuroFlow™ Consortium on the characterization of hematological malignancies for improved accurate diagnosis.1*

 

The BD OneFlow™ B-CLPD T1 is intended for flow cytometric immunophenotyping of B cells in peripheral blood and bone marrow as an aid in the diagnosis of chronic lymphocytic leukemia (CLL) and other B cell chronic lymphoproliferative diseases.

 

Other reagents belonging to the BD OneFlow™ Solution are BD OneFlow™ Lymphoid Screening Tube (LST)BD OneFlow™ Plasma Cell Screening Tube (PCST)BD OneFlow™ Plasma Cell Disorders (PCD) Tube and BD OneFlow™ Acute Leukemia Orientation Tube (ALOT).

 
performance1

View video describing the BD OneFlow™ Solution on the BD FACSLyric™ Flow Cytometer.

FEATURES

The BD OneFlow™ B-CLPD T1 reagent composition

 

AntibodyFluorochromeCloneTarget Populations
CD23FITCEBVCS-5Contributes to the classification of CLL or other B-cell chronic lymphoproliferative diseases

CD10

PEMEM-78Contributes to the classification of CLL or other B-cell chronic lymphoproliferative diseases
CD79bPerCP-Cy 5.5SN8Contributes to the classification of CLL or other B-cell chronic lymphoproliferative diseases
CD19PE-CY 7 SJ25-C1Backbone marker. In common with BD OneFlow™ LST
CD200APCMRC 0X-104Contributes to the classification of CLL or other B-cell chronic lymphoproliferative diseases
CD43APC-H71G10Contributes to the classification of CLL or other B-cell chronic lymphoproliferative diseases
CD20BD Horizon™ V450L27Backbone marker. In common with BD OneFlow™ LST
CD45BD Horizon™ V500-C2D1Backbone marker. In common with BD OneFlow™ LST

 

The EuroFlow antibody panel article1* has a full description of the utility of the antibodies chosen for the BD OneFlow™ B-CLPD T1.

 

 

APPLICATIONS

References

  1. van Dongen JJM, Lhermitte L, Böttcher S, et al. on behalf of the EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708). EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9): 1908-1975. doi: 10.1038/leu.2012.120

  2. Moloney E, Watson H, Barge D, et al. Efficiency and health economic evaluations of BD OneFlow™ Flow Cytometry Reagents for diagnosing chronic lymphoid leukemia. Cytometry B Clin Cytom. 2019;96(6):514-520. doi: 10.1002/cyto.b.21779

  3. Kalina T, Flores-Montero J, van der Velden VHJ, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26(9):1986-2010. doi: 10.1038/leu.2012.122

The BD FACSLyric™ and BD FACSCanto™ II Flow Cytometers are Class 1 Laser Products.

BD OneFlow™ Reagents,  BD FACSLyric™ Flow Cytometer with the BD FACSuite™ Clinical and BD FACSuite™ Applications, BD FACSCanto™ II Flow Cytometer, BD® FC Beads (8-Color, 7-Color, 5-Color and 2-Color Kits), BD OneFlow™ Setup Beads, BD FACSDiva™ CS&T IVD Beads and BD® CS&T Beads are CE marked in compliance with the European In Vitro Diagnostic Medical Device Directive 98/79/EC.

The BD OneFlow™ Solution is intended for professional use only.

The EuroFlow trademark is the property of the EuroFlow Consortium and cannot be reproduced or published without prior written permission from the EuroFlow coordinator (www.euroflow.org).

Cy is a trademark of Global Life Sciences Solutions Germany GmbH or an affiliate doing business as Cytiva.

*This publication refers to EuroFlow and is relevant to the BD OneFlow™ Solution as the BD OneFlow™ Solution demonstrated equivalent results to EuroFlow through a clinical trial.

23-23738-00